Pharma BD Deal Intelligence
Win so far: Roche and Genentech's $150M-upfront, up-to-$12B Recursion alliance is actually executing, reaching $213M in cumulative payments by full-year 2025 after Roche optioned a second neuroscience phenomap in October 2025 — still a fraction of the $12B ceiling across 40 programs.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia in 2021. Of those, 72% are 75 or older. Total payments in 2021 for…
Recursion Pharmaceuticals signed a drug discovery deal with Roche's Genentech worth up to $12 billion in milestones across up to 40 programs in neuroscience…
Recursion is acquiring Exscientia in a $1.7 billion all-stock deal, bringing together two of the most prominent AI drug discovery platforms three years after…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Roche and Genentech entered a transformational, 10+ year drug-discovery collaboration with Recursion (Nasdaq: RXRX) on December 7, 2021, leveraging the Recursion OS image-based AI/ML platform across neuroscience and a single gastrointestinal-oncology indication. Recursion received $150M upfront and is eligible for up to ~$300M+ per program across up to 40 programs, with potential aggregate value exceeding $12B. The collaboration is active and has been executing on its option-and-milestone structure: Roche/Genentech optioned a first GI-oncology program in October 2023, optioned a first neuroscience phenomap (~$30M) in August 2024, and in October 2025 accepted a second neuroscience phenomap - a whole-genome CRISPR knockout map built from 100B+ iPSC-derived microglia - triggering another $30M milestone. As of full-year 2025, Recursion has received $213M in cumulative upfront and milestone payments under the deal, with six Phenomaps accepted and one small-molecule program initiated. (Recursion, separately, merged with Exscientia in August 2024 in a ~$688M all-stock deal, but the Roche/Genentech collaboration continues independently.)
6M US cases/yr · $33.0B US neuroscience drug market 2021 (USD MM, Statista) · 40 Up to 40 programs eligible for milestones (~$300M each)
This collaboration is platform-based rather than indication-specific: Roche/Genentech engaged Recursion's image-based AI/ML drug discovery operating system (Recursion OS) to nominate up to 40 small-molecule programs across neuroscience and a designated oncology indication. The neuroscience scope includes neurodegeneration (Alzheimer's, Parkinson's, ALS) where biology is high-dimensional and screenable in iPSC-derived neuronal phenotypes, and the oncology scope covers a single GI cancer indication. Neuroscience drug discovery has historically had the highest Phase II-to-approval attrition of any major area (~7%, BIO/Biomedtracker 2021), with no disease-modifying treatments for most neurodegenerative diseases at deal signing. The US neuroscience drug market is approximately $33 billion (Statista 2021), with Alzheimer's alone affecting ~6 million Americans (Alzheimer's Association 2021 Facts and Figures). The deal thesis was that Recursion's phenotypic screening of 1+ million compounds against millions of cellular images per week, paired with Roche's translational and clinical engine, could compress timelines and de-risk neuroscience pipeline gaps following the 2022 patent cliff for Roche's neuro franchise.
Big Pharma AI/ML drug discovery deals proliferated through 2020-2022 as the field professionalized. Direct comparable platforms at deal time: Exscientia (Sanofi $5.2B, Jan 2022; Bristol Myers Squibb $1.2B, May 2021); Schrodinger (BMS $2.7B, Nov 2020); Atomwise (Sanofi $1B, Aug 2022); Insitro (BMS $2B, Apr 2020; Genentech multi-target deal Apr 2021); Insilico Medicine (Sanofi $1.2B, Nov 2022); Relay Therapeutics (Genentech $695M, Dec 2020). Recursion's differentiation is image-based phenotypic screening at scale (Phenoprints) versus structure-based (Schrodinger, Atomwise), generative chemistry (Exscientia), or causal genomics (insitro, Relay). Roche's prior AI/ML partners include Genentech-Insitro (Apr 2021, multi-target neurodegeneration), Genentech-Relay (Dec 2020, RAS-MAPK precision oncology), and internal Prescient Design acquisition (Sep 2021, generative biologics). Competitive bracket: Recursion subsequently acquired Cyclica (May 2023), Valence Discovery (May 2023), and merged with Exscientia (Aug 2024) — consolidating the AI biotech landscape into 3-4 platform leaders. The Roche deal remained the largest single AI biotech contract value disclosed at announcement.
Roche and Genentech accepted Recursion's second neuroscience phenomap (a whole-genome CRISPR knockout microglia map from 100B+ iPSC-derived cells), triggering a $30M milestone. By FY2025, cumulative upfront+milestone payments under the collaboration reached $213M, with six Phenomaps accepted and one small-molecule program initiated. The first GI-oncology program was optioned in Oct 2023 and the first neuroscience phenomap in Aug 2024. The collaboration remains active.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Recursion Pharmaceuticals, Inc. (this deal) | 2021 | $12.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals · Neurology deals